Loading...
Loading...
CRNX| Name | Value |
|---|---|
| Revenues | 0.4M |
| Cost of Revenue | 0.8M |
| Gross Profit | -0.4M |
| Operating Expense | 83.2M |
| Operating I/L | -82.8M |
| Other Income/Expense | 8.7M |
| Interest Income | 8.7M |
| Pretax | -74.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -74.1M |
Crinetics Pharmaceuticals, Inc. is a clinical stage pharmaceutical company specializing in rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, Paltusotine, has completed phase III clinical trials for acromegaly and phase II trials for carcinoid syndrome and nonfunctional neuroendocrine tumors. Additionally, Crinetics is developing CRN04777 for congenital hyperinsulinism and CRN04894 for Cushing's and congenital adrenal hyperplasia diseases.
